Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans

Overview

Journal Fed Pract

Specialty Health Services

Date 2020 Jan 2

PMID 31892786

Citations 1

Authors

Renata J M Engler

Emily Brede

Todd Villines

Marina N Vernalis

Affiliations

Soon will be listed here.

Abstract

Newly recognized as a clinical diagnosis, Lp(a) elevation is a major contributor to cardiovascular disease risk should be considered for patients with advanced premature atherosclerosis on imaging or a family history of premature cardiovascular disease, particularly when there are few traditional risk factors.

Citing Articles

Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations.

Ciffone N, McNeal C, McGowan M, Ferdinand K Am Heart J Plus. 2024; 38:100350.

PMID: 38510747 PMC: 10945898. DOI: 10.1016/j.ahjo.2023.100350.

References

Schwartz G, Steg P, Szarek M, Bhatt D, Bittner V, Diaz R . Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018; 379(22):2097-2107. DOI: 10.1056/NEJMoa1801174. View

Downs J, OMalley P . Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2015; 163(4):291-7. DOI: 10.7326/M15-0840. View

van der Valk F, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul J . Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation. 2016; 134(8):611-24. PMC: 4995139. DOI: 10.1161/CIRCULATIONAHA.116.020838. View

Wang J, Zhang C, Gong J, Zhu Y, Fu L, Wang X . Development of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a) by using purified human oxidized lipoprotein(a) autoantibodies as capture antibody. Clin Chim Acta. 2007; 385(1-2):73-8. DOI: 10.1016/j.cca.2007.06.023. View

Aguib Y, Suwaidi J . The Copenhagen City Heart Study (Østerbroundersøgelsen). Glob Cardiol Sci Pract. 2016; 2015(3):33. PMC: 4625209. DOI: 10.5339/gcsp.2015.33. View

Fryar C, Chen T, Li X . Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999-2010. NCHS Data Brief. 2012; (103):1-8. View

Nave A, Lange K, Leonards C, Siegerink B, Doehner W, Landmesser U . Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015; 242(2):496-503. DOI: 10.1016/j.atherosclerosis.2015.08.021. View

Varvel S, McConnell J, Tsimikas S . Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. Arterioscler Thromb Vasc Biol. 2016; 36(11):2239-2245. DOI: 10.1161/ATVBAHA.116.308011. View

. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989; 129(4):687-702. View

10.

Nicholls S, Ruotolo G, Brewer H, Wang M, Liu L, Willey M . Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol. 2016; 10(3):519-527.e4. DOI: 10.1016/j.jacl.2015.11.014. View

11.

Kamstrup P, Tybjaerg-Hansen A, Nordestgaard B . Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2013; 63(5):470-7. DOI: 10.1016/j.jacc.2013.09.038. View

12.

Roth G, Johnson C, Abajobir A, Abd-Allah F, Abera S, Abyu G . Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70(1):1-25. PMC: 5491406. DOI: 10.1016/j.jacc.2017.04.052. View

13.

Fulcher J, OConnell R, Voysey M, Emberson J, Blackwell L, Mihaylova B . Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976):1397-405. DOI: 10.1016/S0140-6736(14)61368-4. View

14.

Lieb W, Enserro D, Larson M, Vasan R . Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community. Open Heart. 2018; 5(1):e000722. PMC: 5786911. DOI: 10.1136/openhrt-2017-000722. View

15.

Yeang C, Hung M, Byun Y, Clopton P, Yang X, Witztum J . Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol. 2016; 10(3):594-603. DOI: 10.1016/j.jacl.2016.01.005. View

16.

Kamstrup P, Benn M, Tybjaerg-Hansen A, Nordestgaard B . Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2007; 117(2):176-84. DOI: 10.1161/CIRCULATIONAHA.107.715698. View

17.

Danik J, Rifai N, Buring J, Ridker P . Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006; 296(11):1363-70. DOI: 10.1001/jama.296.11.1363. View

18.

Schwartz G, Ballantyne C, Barter P, Kallend D, Leiter L, Leitersdorf E . Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2017; 3(2):164-168. PMC: 5838593. DOI: 10.1001/jamacardio.2017.3833. View

19.

Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini G . Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol. 2012; 21(1):57-64. DOI: 10.1177/2047487312460020. View

20.

Albers J, Slee A, OBrien K, Robinson J, Kashyap M, Kwiterovich Jr P . Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013; 62(17):1575-9. PMC: 3800510. DOI: 10.1016/j.jacc.2013.06.051. View